Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LIPO 
Lipella Pharmaceuticals Inc. Common Stock (LIPO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: LIPO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.91% | Avg. Invested days 10 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.54M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta -0.05 | 52 Weeks Range 0.51 - 4.69 | Updated Date 10/12/2025 |
52 Weeks Range 0.51 - 4.69 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1564.19% |
Management Effectiveness
Return on Assets (TTM) -118.45% | Return on Equity (TTM) -248.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 80395 | Price to Sales(TTM) 5.41 |
Enterprise Value 80395 | Price to Sales(TTM) 5.41 | ||
Enterprise Value to Revenue 0.15 | Enterprise Value to EBITDA -4.4 | Shares Outstanding 4620837 | Shares Floating 4329355 |
Shares Outstanding 4620837 | Shares Floating 4329355 | ||
Percent Insiders 6.53 | Percent Institutions 1.35 |
Upturn AI SWOT
Lipella Pharmaceuticals Inc. Common Stock
Company Overview
History and Background
Lipella Pharmaceuticals Inc. is a biopharmaceutical company focused on developing new and improved treatments for lower urinary tract diseases and other unmet medical needs. It was founded in 2002.
Core Business Areas
- Pharmaceutical Development: Focused on developing and commercializing novel therapies for urologic diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their product candidates.
- Drug Delivery Technology: Utilizing innovative drug delivery technologies to enhance treatment outcomes.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure includes departments for research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- LP-10: LP-10 is Lipella's lead product candidate, a delayed-release oral formulation of tacrolimus being developed for hemorrhagic cystitis (HC). There is currently no approved treatment for HC. Competitors include off-label use of various medications and supportive care. Market share data for LP-10 is not currently available as it is still in development, but the market for HC treatment could be significant if LP-10 is approved. Competitors include various off-label treatments by companies like Pfizer, Novartis etc.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development.
Positioning
Lipella Pharmaceuticals is positioned as a specialty pharmaceutical company focused on niche markets with unmet medical needs. Their competitive advantage lies in their proprietary drug delivery technology and focus on urologic diseases.
Total Addressable Market (TAM)
The TAM for HC treatment is estimated to be significant, potentially reaching hundreds of millions of dollars if an effective and approved therapy becomes available. Lipella is positioned to capture a significant portion of this TAM with LP-10, if approved.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on a single product candidate (LP-10)
- Lack of commercialization experience
Opportunities
- Successful completion of clinical trials for LP-10
- Partnerships with larger pharmaceutical companies
- Expansion into other urologic indications
Threats
- Clinical trial failures
- Regulatory delays
- Competition from other companies developing treatments for HC
Competitors and Market Share
Key Competitors
Competitive Landscape
Lipella competes with companies offering off-label treatments for HC and other companies developing novel therapies for urologic diseases. The competitive landscape is fragmented, with no dominant player.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's development stage.
Future Projections: Future growth depends on the successful development and commercialization of LP-10. Analyst estimates vary widely depending on the probability of success.
Recent Initiatives: Recent initiatives include advancing LP-10 through clinical trials and seeking strategic partnerships.
Summary
Lipella Pharmaceuticals is a development-stage company with potential upside if LP-10 is successfully developed and commercialized. The company faces significant risks, including clinical trial failures and regulatory hurdles. Its focus on unmet medical needs and proprietary technology could provide a competitive advantage, but it must carefully manage its resources and execute its clinical development plan. The company requires strategic partnerships to accelerate growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lipella Pharmaceuticals Inc. SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lipella Pharmaceuticals Inc. Common Stock
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2022-12-19 | Co-Founder, Chairman, CEO, President, Secretary & Treasurer Dr. Jonathan Kaufman M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://lipella.com |
Full time employees 5 | Website https://lipella.com | ||
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.